Cero Therapeutics Holdings Stock Fundamentals
| CEROW Stock | 0.01 0 14.29% |
CERo Therapeutics Holdings fundamentals help investors to digest information that contributes to CERo Therapeutics' financial success or failures. It also enables traders to predict the movement of CERo Stock. The fundamental analysis module provides a way to measure CERo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CERo Therapeutics stock.
CERo |
CERo Therapeutics Holdings Company Net Income Analysis
CERo Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current CERo Therapeutics Net Income | (2.54 K) |
Most of CERo Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CERo Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, CERo Therapeutics Holdings reported net income of (2,536). This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The net income for all United States stocks is 100.0% higher than that of the company.
CERo Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CERo Therapeutics's current stock value. Our valuation model uses many indicators to compare CERo Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CERo Therapeutics competition to find correlations between indicators driving CERo Therapeutics's intrinsic value. More Info.CERo Therapeutics Holdings is number one stock in return on asset category among its peers. It also is number one stock in number of shares shorted category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value CERo Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.CERo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CERo Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CERo Therapeutics could also be used in its relative valuation, which is a method of valuing CERo Therapeutics by comparing valuation metrics of similar companies.CERo Therapeutics is currently under evaluation in net income category among its peers.
CERo Fundamentals
| Return On Asset | -0.45 | ||||
| Number Of Shares Shorted | 133.08 K | ||||
| EBITDA | (2.44 M) | ||||
| Net Income | (2.54 K) | ||||
| Total Debt | 1.55 M | ||||
| Book Value Per Share | (2.27) X | ||||
| Cash Flow From Operations | (1.52 K) | ||||
| Beta | -0.46 | ||||
| Total Asset | 8.56 M | ||||
| Retained Earnings | (14.2 M) | ||||
| Working Capital | 5.91 M | ||||
| Net Asset | 8.56 M |
About CERo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CERo Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CERo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CERo Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 20.1 K | 21.1 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CERo Stock Analysis
When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.